Key findings of an extensive survey of MPN patients, funded by Incyte Corporation
This article, published in BioMed Central Cancer, reviews the findings of the MPN Landmark Survey, the first study ever to assess patient perceptions of MPN disease burden and health care. These findings support those of previous research about symptom burden experienced by patients with MPNs.
Recognizing and treating the patient with high-risk disease
Incyte Corporation has partnered with Dr Kim-Hien Dao—who treats primarily high-risk patients at Oregon Health & Science University in Portland, Oregon—to discuss 2 controversial issues in the recognition of patients with high-risk polycythemia vera (PV). A variety of clinical presentations point to higher-risk features of PV, in addition to age >60 years and prior thrombotic events. Additionally, patients with poorly controlled hematocrit should be followed and managed very closely to reduce life-threatening complications from PV.
Insights from this collaboration can be found in our third full article from the PV State of Mind platform, an ongoing program that provides a framework for the discussion of topics and recent developments to help clinicians better understand this serious disease.
Incyte Corporation has partnered with Dr Jerry L. Spivak— a highly regarded expert in chronic myeloproliferative disorders—to discuss the phenotypic variability of polycythemia vera (PV), the need for identification and early institution of therapy for the subset of patients who may be at risk for a more aggressive disease course, and the data surrounding gene expression profiling as a clinical assessment to help inform future patient identification analyses and risk management.
Insights from this collaboration can be found in our second full article from the PV State of Mind program, an ongoing program that discusses important controversial issues in this progressive field.
Jerry L. Spivak, MD The Johns Hopkins Hospital and Johns Hopkins Center for the Chronic Myeloproliferative Disorders, Baltimore, Maryland
Emerging diagnostic and risk stratification criteria
Incyte Corporation has partnered with Dr Rami S. Komrokji—Clinical Director of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida—to explore the evolution of diagnostic and risk stratification criteria in polycythemia vera (PV), particularly in relation to their ability to predict disease progression, hematologic transformation, and overall survival.
Insights from this collaboration can be found in our first full article from the PV State of Mind program, an ongoing series that discusses the relevant topics in PV today.
Rami S. Komrokji, MD Moffitt Cancer Center, Tampa, Florida
About PV State of Mind
See polycythemia vera through the eyes of experts
PV State of Mind provides a framework for the discussion of topics and recent developments to help clinicians better understand this serious disease. Areas of investigation may include:
Limitations of current diagnostic criteria
Evolving risk stratification models
Emerging indicators for more aggressive forms of disease
See how new models are being developed to reflect a more contemporary understanding of diagnosis and risk in PV.
Download the full articles or podcasts to learn about these thought leaders' perspectives in polycythemia vera.
Kim-Hien Dao, DO, PhD
Recognizing and treating the patient with high-risk polycythemia vera
Jerry L. Spivak, MD
Focus on aggressive polycythemia vera
Rami S. Komrokji, MD
Polycythemia vera: Emerging diagnostic and risk stratification criteria
Click below to hear audio clips from the interviews. Feel free to download or share the clips with colleagues.
Kim-Hien Dao, DO, PhD
What are some signs that may help identify patients with high-risk polycythemia vera (PV)?
Polycythemia vera may be less alarming than most cancers because of its long...Read Moreclinical course. This may cause clinicians not to manage the disease aggressively. Dr Dao has identified indicators that can help clinicians recognize patients with polycythemia vera who are at higher risk than may be apparent.
I guess really the patients that are in danger are the patients who don’t have access to a hematologist. They get managed by their primary care who may not fully understand the risks of having PV and uncontrolled hematocrit. That’s the scenario that I’ve seen. And then for the hematologist, I think that because patients do well for a while, I think sometimes they forget the hematocrit goal or don’t realize how important it is to reduce the patient’s risk for thrombotic events by getting the hematocrit below 45 for men and then below 42 for women.
Symptoms associated with PV is a marker of cytokine levels in their blood, and uncontrolled symptoms might be a marker that their PV is very active and their hematocrit is very high. The ultimate red flag, of course, is presenting with a thrombotic event.
Do you consider other risk factors beyond advanced age and history of thrombosis?
In addition to advanced age and history of thrombosis—the classic risk...Read Morefactors for a thrombotic event in polycythemia vera (PV)—there are other factors that might influence prognosis.
I consider classic cardiovascular risk factors as something that would worry me and want me to make sure that a patient has a better controlled hematocrit. Someone who has diabetes or had a high-grade heart attack, those are patients I would worry about in addition to age and prior thrombosis of wanting to control their hematocrit tightly. I’m worried about what resistance to prior therapy means in terms of hematocrit control, not by itself being necessarily a biomarker that they have worse disease. And then excessive symptoms or complications with PV—that’s a concerning feature that would want me to make sure that a patient has a better controlled hematocrit.
Do patients with polycythemia vera and resistance or intolerance to hydroxyurea present a special problem?
Hydroxyurea is often the first-line myelosuppressive agent, but patients can be...Read Moreintolerant of or develop resistance to hydroxyurea. These patients present a special problem.
If the patient is intolerant, sometimes those early symptoms include fatigue, fevers, night sweats, and then, of course, ulceration. The ulcers can happen any time, but intolerance like nausea, gastrointestinal upset, fevers, and fatigue can happen within days or weeks of starting therapy.
I think if you were looking at true failure, not because of intolerance, but truly that you can’t control the hematocrit, I usually give Hydrea® (hydroxyurea) 2 to 3 months with escalating doses before we call it a failure.
What would you say is the most common mistake in the management of polycythemia vera (PV)?
Dr. Dao has seen one clinical practice repeatedly that she thinks puts patients...Read Moreat unnecessary risk and compromises outcomes.
The mistake I see over and over again is that these patients are not being managed close enough when they first get diagnosed with PV. Look for treatment effectiveness of the hydroxyurea dose, especially and frequently in that early phase, in that first 6 months when you’re trying to get patients to a steady-state level of hydroxyurea and control. What I see all too often is that these patients get diagnosed, they start Hydrea® (hydroxyurea) but they don’t get follow-up for 3 to 6 months and their hematocrit is still uncontrolled, you know, like 50. My advice would be that early PV management is very important, so institute phlebotomies immediately if needed to bring their hematocrit below 45—and it could be very frequent initially. And then frequent check of their CBC (complete blood count) the first 6 months; check their CBC every 4 weeks, probably until they’re at a steady-state target hematocrit, and then you can bring down the frequency of follow-up.
Jerry L. Spivak, MD
Patients with polycythemia vera can present with various combinations of elevated levels of red cells, white cells, and/or platelets. Is there any prognostic value to these presentations?
Polycythemia vera may present as erythrocytosis, leukocytosis, thrombocytosis, or...Read Morevarious combinations of the above. In his clinical experience, Dr Spivak has seen different outcomes associated with these different presentations.
Polycythemia vera is a disease that involves a stem cell and so, therefore, you’re gonna have increased numbers of red cells, increased numbers of white cells, and increased numbers of platelets. Now, the disease is very variable in that regard. You can have patients who have the JAK2V617F mutation that only have erythrocytosis. They’re not common but they can live; we’ve seen them for at least 10 years or more. Then you will have patients who have an elevation of the red cells and the platelets, okay, and not the white cells. When I see that, I find that generally is a clue that they’re gonna do very well. Then you have patients who come in and they’re making too many red cells, too many white cells, and too many platelets. They have the more sort of aggressive-type disease in a way; they’re more likely to get splenomegaly and do things, you know, in a more aggressive fashion. So polycythemia vera comes in all flavors. Now, the important thing to remember is that it’s not the platelets or the white cells that determine prognosis, it’s the stem cell.
A subset of patients with polycythemia vera will do poorly.
Dr Spivak published a study in the New England Journal of Medicine in which...Read Morehe described the identification of a subset of patients with aggressive, high-risk polycythemia vera.
If you go back in the literature, and you can go back into the early ‘60s and just come forward, what you’re gonna find repeatedly is that there is a segment of polycythemia vera patients, and it’s a minimum of 10%—it might be 15%—that have a more aggressive disease, but the rest of the patients do not. And what we did very simply was we said we interrogated what genes are these stem cells making. And we could divide polycythemia vera patients into 2 groups: those are gonna do well and those who are gonna do poorly. People who do badly, their stem cells are making a different set of genes than the people who do well. And that is immutable data, that is, genetic data.
Do you think differently when assessing polycythemia vera in men and women?
The CYTO-PV Study used a hematocrit target of <45% in polycythemia vera and...Read Moresaw a significantly lower rate of cardiovascular death and major thrombosis than in patients with a hematocrit target of 45% to 50%.
The reason that I differentiate women with polycythemia from men with polycythemia is that under normal circumstances, women have a smaller blood volume than men do. And if you use the male hematocrit for a female with polycythemia vera, then you are essentially allowing the female patient to have a larger blood volume than a normal woman would have. So this is just common sense physiology. So, if you come back to where we find most patients with polycythemia vera these days, we sort of diagnose them early because people tend to go to doctors more frequently and we have tests that we apply across the board, you know, in terms of complete blood counts. So people are picked up earlier and their hematocrits aren’t as high, so this—the idea of seeing someone with hematocrit of 55 or 60%— which should always be a red light, isn’t usually there. And so you will see women coming in with hematocrit of 48% or 46%. But a normal female hematocrit begins at 36 and sort of goes up and sort of ends about 42%. So, if you leave them at 45% or higher, you’re not completely treating them.
Rami S. Komrokji, MD
Proposed revisions to the WHO diagnostic criteria for PV
Diagnostic criteria for polycythemia vera have evolved since...Read Morethe Polycythemia Vera Study Group, and continue to evolve. Since the 2008 revision of the World Health Organization Diagnostic Criteria for polycythemia vera there have been several proposals for further revision, particularly in the last few years.
There had been different set of criteria in the past to diagnosis. There were the P.V. study group diagnostic criteria. Most recently, what's mostly used was the WHO criteria which require hemoglobin more than 18.5 in men or 16.5 in female and the presence of JAK2 V617 or JAK2 exon 12, the (cloning) marker. Those are the two major criteria. Then the minor criteria include bone marrow findings that are consistent with MPN such as hypercellularity, megakaryocyte clustering, low serum EPO and endogenous erythroid colony formation in vivo. Those are the current criteria and you either have two major or you have one major and two minor. The proposal for revision by the WHO includes changing the threshold for hemoglobin to 16.5 in male and 16 grams per deciliter in female. And obviously presence of a JAK2 mutation remained. The proposal for the revision includes the suggestion to move the bone marrow findings as well to a major criterion. The only minor criteria that will remain would be the low serum EPO level. Most of the cases actually, if they are straightforward, you will make the diagnosis by the presence of erythrocytosis and the JAK2 mutation. You probably don't need the bone marrow to make the diagnosis.
What prognostic factors are currently used to guide selection of therapy?
Currently, patients are divided into low-risk or high-risk groups...Read Moreaccording to two factors: age greater than 60 years and a prior thrombotic event.
There are two types or two ways of risk stratification. The classic one to guide treatment and a more comprehensive one to predict outcome. One is basically to decide on treatment, and this is the classical way that we've used for P vera and for essential thrombocythemia. So, we divide the patients into two risk groups: those that are at increased risk of developing thrombosis and that include patients above age of 60, and those that had history of thrombosis, whether arterial or venous. So, those are coded with the high risk group compared to a low risk – lower risk group that are below age of 60 and never had an event. Obviously, this is a good starting point but it does have some limitations. Yes, patients above age of 60 do have increased risk of thrombosis but events do occur in younger patients. Now, the type of events may be different, younger patients may be getting more DVT or PE while older patients sometimes tend to get more arterial events. But younger patients are not immune from getting thrombotic events. We know now that there are other factors that may contribute to increased risk of thrombosis such as the leukocyte count, the platelet count.
What are some of the additional risk factors proposed in the literature?
In addition to the conventional risk stratification factors of age and thrombotic...Read Morehistory, new factors are being proposed that may be prognostic for survival, disease progression, or hematologic transformation.
We also look at different variables. We definitely look at the leukocyte count. I think there is evidence that the higher leukocyte count, maybe the higher the thrombotic event. Platelet count being high could correlate with thrombotic event. Some people look at like, for example, the JAK2 allele burden related homozygotic or heterozygotic because that could have implications many more on disease progression to fibrosis rather than risk of thrombosis. And then we are starting to see people looking at molecular profiling in those patients, looking at other molecular events which are probably more studied in myelofibrosis at this point. We're starting to learn about those as well in P vera but they are not yet established into any risk stratification.
As part of the PV State of Mind program, a slide kit summary from each interview is available to download at your convenience.
This website is provided by Incyte Corporation (“Incyte”).
PLEASE READ AND REVIEW THE FOLLOWING TERMS CAREFULLY BEFORE USING THE WEBSITE. The following terms govern your use of the website, and by using the website you agree to be bound by and to comply with such terms. If you do not agree, you may not access or use the website. Incyte reserves the right to modify these terms from time to time without notice.
Use of the website
While Incyte uses reasonable efforts to include up-to-date and accurate information on the website, INCYTE MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE ACCURACY, COMPLETENESS OR SUITABILITY OF THE INFORMATION MADE AVAILABLE ON THE WEBSITE, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. THE INFORMATION ON THE WEBSITE IS PROVIDED TO YOU AS IS. Incyte disclaims any and all liability related to use of the website or any website linked to this notice. Incyte shall not have any obligation to update the website. Your access and use of the website, including without limitation, the information made available on the website, is at your own risk. You agree that you will not make any claim against Incyte based on your access or use, or inability to use, the website or its contents. Incyte shall not be liable in any manner whatsoever for any direct, indirect, consequential, incidental, special or punitive damages arising out of your access, use or inability to use the website or its contents, or errors or omissions in the content thereof, including without limitation, loss of use, data or profits, whether in an action based on contract, negligence or other tort.
The website and the information contained or referenced on the website is intended for informational, personal and non-commercial purposes only. The website does not provide medical or professional services or advice and should not be relied upon as the basis of any healthcare decision. Persons requiring diagnosis or treatment or with questions specific to an individual are urged to contact their healthcare provider.
The website is only intended for use by U.S. residents who are at least eighteen (18) years of age. You should not construe anything on the website as a promotion of or solicitation for any product or service that is not authorized by the laws and regulations of the jurisdiction in which you are located.
You may not use the website or its contents for any purpose that is unlawful.
Copyright and other intellectual property rights
The website, and the information which it contains, is the property of Incyte, and is protected from unauthorized copying and dissemination by United States copyright law, international conventions and other intellectual property laws. The trademarks, service marks, logos, or other intellectual property displayed on the website are owned by Incyte except as otherwise noted. Nothing on the website should be construed to grant any license or right in or to any trademarks, service mark, logos or other intellectual property rights. All rights are reserved by the owners of each trademark, service mark, logo, or other intellectual property, except as otherwise described in this notice.
Links to third-party websites
Information submitted to Incyte
No offer and no solicitation
The information provided on the website does not constitute an, and is not provided in relation to any, offer of or solicitation for the purchase or disposal of, trading or any transaction in any Incyte securities. Investors must not rely on this information when making investment decisions.
Incyte reserves the right to change the content of the website at any time without notice to you. Incyte reserves the right to terminate your access or use of the website at any time. If your violation of these terms causes harm to others, you shall indemnify and hold Incyte harmless from and against any and all liabilities, losses, damage and expenses related thereto. These terms shall be governed by the laws of the State of Delaware, without giving effect to its conflict of laws principles. You hereby submit to the jurisdiction of the state and federal courts in Wilmington, Delaware in any proceeding relating to the website or its contents. These terms set forth the entire agreement between you and Incyte with respect to the subject matter hereof.
Personally Identifiable Information
With respect to the website, Incyte will only collect, store or use personally identifiable information (that is, any information by which you can be identified, such as name, address, e-mail address, and telephone number, which we refer to as “Your Information”), when it is voluntarily submitted to us. You have the option not to provide any of Your Information to us. If you do provide Your Information to us, Your Information may be used to fulfill your request for information, to provide you with other information or services, to market future products and services which we think may be of interest to you, to communicate with you for other purposes, to respond to requests you may make of us, and from time to time, we may refer to Your Information to better understand your needs and how we can improve the website’s services and we may use Your Information within the company for performing marketing studies or other analyses. We will not sell Your Information to any other company or organization. We may share Your Information with other companies or organizations that work with, or on behalf of, Incyte to provide products and services, but subject to limitations on their use or disclosure. If you choose not to provide the information we may request, you can still visit most of the website, but you may be unable to access certain options and services. In general, you can visit the website without telling us who you are or revealing any personal information about yourself. We may track the total number of visitors to our site, the number of visitors to each page of our site, and the domain names of our visitors’ Internet service providers and analyze this data for trends and statistics, but the individual user remains anonymous. From time to time we may share such aggregated data with third parties assisting us in market research. You may update Your Information and opt out of receiving certain communications or have us stop contacting you by accessing your registration or profile. You may also opt out of receiving e-mails and other communications from us by using the features or other communication means contained in e-mails sent to you. Such requests will be subject to any applicable legal and ethical reporting or document filing or retention obligations.
Release in Limited Circumstances
In certain limited circumstances, Incyte may be required to release Your Information in response to a court order, subpoena, search warrant, law, or regulation. We also reserve the right to cooperate with law enforcement authorities in investigating and prosecuting users who violate our rules or engage in behavior that is illegal or harmful to other websites.
Privacy of Children
We are committed to protecting the privacy of children. This site is not intended, or designed, to attract children under the age of eighteen.
The website has security measures in place, including the use of industry standard secure socket layer encryption (SSL), to protect the confidentiality of any of Your Information that you volunteer. However, to take advantage of this, your browser must support encryption protection. Regardless of the precautions taken by you or by us, perfect security does not exist on the Internet. We cannot ensure or warrant the security of any information you transmit to us, and you transmit such information at your own risk.
Links to Other Sites
Intended for use by United States residents who are healthcare professionals. Any personally identifiable information submitted at the website goes to Incyte in the United States only and by submitting personally identifiable information to the website, you waive any rights you may have under any law of any other country or region.